Ligand Pharmaceuticals Incorporated (LGND)
USD 99.8
(-3.21%)
USD 99.8
(-3.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 833.06 Million USD | 9.23% |
| 2022 | 762.66 Million USD | -41.4% |
| 2021 | 1.3 Billion USD | -4.47% |
| 2020 | 1.36 Billion USD | -7.28% |
| 2019 | 1.46 Billion USD | 16.54% |
| 2018 | 1.26 Billion USD | 87.89% |
| 2017 | 671.02 Million USD | 11.54% |
| 2016 | 601.58 Million USD | 12.67% |
| 2015 | 533.92 Million USD | 106.93% |
| 2014 | 258.02 Million USD | 146.42% |
| 2013 | 104.71 Million USD | 0.43% |
| 2012 | 104.26 Million USD | -14.79% |
| 2011 | 122.35 Million USD | 61.93% |
| 2010 | 75.55 Million USD | -33.54% |
| 2009 | 113.69 Million USD | -33.68% |
| 2008 | 171.44 Million USD | -1.06% |
| 2007 | 173.27 Million USD | -46.86% |
| 2006 | 326.05 Million USD | 3.63% |
| 2005 | 314.61 Million USD | -5.37% |
| 2004 | 332.46 Million USD | 10.36% |
| 2003 | 301.25 Million USD | 11.32% |
| 2002 | 270.6 Million USD | 130.36% |
| 2001 | 117.47 Million USD | 3.57% |
| 2000 | 113.42 Million USD | -15.73% |
| 1999 | 134.6 Million USD | -13.72% |
| 1998 | 156 Million USD | 45.25% |
| 1997 | 107.4 Million USD | 5.19% |
| 1996 | 102.1 Million USD | 9.08% |
| 1995 | 93.6 Million USD | 100.43% |
| 1994 | 46.7 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 913.86 Million USD | 9.7% |
| 2024 Q2 | 866.4 Million USD | -5.19% |
| 2023 Q1 | 811.07 Million USD | 6.35% |
| 2023 Q3 | 769.21 Million USD | 1.46% |
| 2023 Q4 | 833.06 Million USD | 8.3% |
| 2023 FY | 833.06 Million USD | 9.23% |
| 2023 Q2 | 758.1 Million USD | -6.53% |
| 2022 FY | 762.66 Million USD | -41.4% |
| 2022 Q2 | 1.07 Billion USD | -2.61% |
| 2022 Q1 | 1.1 Billion USD | -15.08% |
| 2022 Q4 | 762.66 Million USD | -27.41% |
| 2022 Q3 | 1.05 Billion USD | -2.39% |
| 2021 FY | 1.3 Billion USD | -4.47% |
| 2021 Q1 | 1.29 Billion USD | -4.93% |
| 2021 Q2 | 1.25 Billion USD | -3.0% |
| 2021 Q3 | 1.27 Billion USD | 1.38% |
| 2021 Q4 | 1.3 Billion USD | 2.18% |
| 2020 Q4 | 1.36 Billion USD | 9.21% |
| 2020 Q3 | 1.24 Billion USD | 0.36% |
| 2020 Q2 | 1.24 Billion USD | 4.81% |
| 2020 Q1 | 1.18 Billion USD | -19.29% |
| 2020 FY | 1.36 Billion USD | -7.28% |
| 2019 FY | 1.46 Billion USD | 16.54% |
| 2019 Q2 | 1.8 Billion USD | -5.86% |
| 2019 Q3 | 1.54 Billion USD | -14.12% |
| 2019 Q4 | 1.46 Billion USD | -5.05% |
| 2019 Q1 | 1.91 Billion USD | 51.81% |
| 2018 Q3 | 2.1 Billion USD | 13.32% |
| 2018 FY | 1.26 Billion USD | 87.89% |
| 2018 Q4 | 1.26 Billion USD | -40.13% |
| 2018 Q2 | 1.85 Billion USD | 146.24% |
| 2018 Q1 | 754.66 Million USD | 12.47% |
| 2017 Q2 | 640.02 Million USD | 1.64% |
| 2017 Q1 | 629.72 Million USD | 4.68% |
| 2017 FY | 671.02 Million USD | 11.54% |
| 2017 Q4 | 671.02 Million USD | 1.31% |
| 2017 Q3 | 662.33 Million USD | 3.49% |
| 2016 Q3 | 600.86 Million USD | -2.58% |
| 2016 Q1 | 613.43 Million USD | 14.89% |
| 2016 Q4 | 601.58 Million USD | 0.12% |
| 2016 FY | 601.58 Million USD | 12.67% |
| 2016 Q2 | 616.79 Million USD | 0.55% |
| 2015 Q1 | 263.22 Million USD | 2.01% |
| 2015 Q3 | 521.7 Million USD | 71.18% |
| 2015 FY | 533.92 Million USD | 106.93% |
| 2015 Q2 | 304.76 Million USD | 15.78% |
| 2015 Q4 | 533.92 Million USD | 2.34% |
| 2014 Q2 | 99.84 Million USD | -5.33% |
| 2014 Q3 | 272.28 Million USD | 172.7% |
| 2014 Q4 | 258.02 Million USD | -5.23% |
| 2014 FY | 258.02 Million USD | 146.42% |
| 2014 Q1 | 105.47 Million USD | 0.72% |
| 2013 Q2 | 99.57 Million USD | 1.23% |
| 2013 Q3 | 101.67 Million USD | 2.12% |
| 2013 Q1 | 98.36 Million USD | -5.66% |
| 2013 Q4 | 104.71 Million USD | 2.99% |
| 2013 FY | 104.71 Million USD | 0.43% |
| 2012 Q2 | 104.59 Million USD | -6.44% |
| 2012 Q3 | 97.5 Million USD | -6.78% |
| 2012 Q4 | 104.26 Million USD | 6.93% |
| 2012 FY | 104.26 Million USD | -14.79% |
| 2012 Q1 | 111.79 Million USD | -8.62% |
| 2011 FY | 122.35 Million USD | 61.93% |
| 2011 Q2 | 127.43 Million USD | -5.01% |
| 2011 Q1 | 134.15 Million USD | 77.55% |
| 2011 Q4 | 122.35 Million USD | -0.09% |
| 2011 Q3 | 122.46 Million USD | -3.9% |
| 2010 Q4 | 75.55 Million USD | -32.88% |
| 2010 Q3 | 112.56 Million USD | -11.78% |
| 2010 Q2 | 127.59 Million USD | -4.51% |
| 2010 Q1 | 133.62 Million USD | -5.77% |
| 2010 FY | 75.55 Million USD | -33.54% |
| 2009 Q4 | 141.8 Million USD | 21.11% |
| 2009 Q1 | 139.58 Million USD | -18.58% |
| 2009 Q2 | 129.17 Million USD | -7.46% |
| 2009 Q3 | 117.08 Million USD | -9.36% |
| 2009 FY | 113.69 Million USD | -33.68% |
| 2008 FY | 171.44 Million USD | -1.06% |
| 2008 Q1 | 166.26 Million USD | -4.05% |
| 2008 Q2 | 160.02 Million USD | -3.75% |
| 2008 Q3 | 147.19 Million USD | -8.02% |
| 2008 Q4 | 171.44 Million USD | 16.48% |
| 2007 FY | 173.27 Million USD | -46.86% |
| 2007 Q1 | 524.81 Million USD | 60.96% |
| 2007 Q2 | 228.47 Million USD | -56.47% |
| 2007 Q3 | 211.52 Million USD | -7.42% |
| 2007 Q4 | 173.27 Million USD | -18.08% |
| 2006 Q3 | 231.86 Million USD | -18.91% |
| 2006 Q4 | 326.05 Million USD | 40.62% |
| 2006 Q1 | 288.68 Million USD | -8.24% |
| 2006 Q2 | 285.93 Million USD | -0.96% |
| 2006 FY | 326.05 Million USD | 3.63% |
| 2005 Q1 | 313.25 Million USD | -5.78% |
| 2005 FY | 314.61 Million USD | -5.37% |
| 2005 Q2 | 301.72 Million USD | -3.68% |
| 2005 Q3 | 306.04 Million USD | 1.43% |
| 2005 Q4 | 314.61 Million USD | 2.8% |
| 2004 FY | 332.46 Million USD | 10.36% |
| 2004 Q4 | 332.46 Million USD | 15.18% |
| 2004 Q3 | 288.65 Million USD | 1.17% |
| 2004 Q2 | 285.31 Million USD | -3.02% |
| 2004 Q1 | 294.18 Million USD | -2.35% |
| 2003 Q1 | 241.17 Million USD | -10.88% |
| 2003 Q3 | 272.79 Million USD | 20.21% |
| 2003 Q2 | 226.93 Million USD | -5.91% |
| 2003 FY | 301.25 Million USD | 11.32% |
| 2003 Q4 | 301.25 Million USD | 10.43% |
| 2002 Q1 | 118.9 Million USD | 1.22% |
| 2002 FY | 270.6 Million USD | 130.36% |
| 2002 Q3 | 118.02 Million USD | -7.54% |
| 2002 Q4 | 270.6 Million USD | 129.28% |
| 2002 Q2 | 127.65 Million USD | 7.36% |
| 2001 FY | 117.47 Million USD | 3.57% |
| 2001 Q2 | 124.7 Million USD | -1.2% |
| 2001 Q3 | 116.96 Million USD | -6.21% |
| 2001 Q4 | 117.47 Million USD | 0.44% |
| 2001 Q1 | 126.22 Million USD | 11.28% |
| 2000 FY | 113.42 Million USD | -15.73% |
| 2000 Q3 | 115.01 Million USD | -10.84% |
| 2000 Q1 | 129.55 Million USD | -3.75% |
| 2000 Q2 | 128.99 Million USD | -0.44% |
| 2000 Q4 | 113.42 Million USD | -1.38% |
| 1999 Q4 | 134.6 Million USD | 2.2% |
| 1999 Q2 | 123.3 Million USD | -8.87% |
| 1999 Q1 | 135.3 Million USD | -13.27% |
| 1999 FY | 134.6 Million USD | -13.72% |
| 1999 Q3 | 131.7 Million USD | 6.81% |
| 1998 Q3 | 125.7 Million USD | 52.73% |
| 1998 Q1 | 89.5 Million USD | -16.67% |
| 1998 FY | 156 Million USD | 45.25% |
| 1998 Q4 | 156 Million USD | 24.11% |
| 1998 Q2 | 82.3 Million USD | -8.04% |
| 1997 Q3 | 77.9 Million USD | -11.28% |
| 1997 FY | 107.4 Million USD | 5.19% |
| 1997 Q4 | 107.4 Million USD | 37.87% |
| 1997 Q2 | 87.8 Million USD | -8.54% |
| 1997 Q1 | 96 Million USD | -5.97% |
| 1996 Q2 | 76.7 Million USD | -10.4% |
| 1996 Q4 | 102.1 Million USD | 51.04% |
| 1996 Q1 | 85.6 Million USD | -8.55% |
| 1996 Q3 | 67.6 Million USD | -11.86% |
| 1996 FY | 102.1 Million USD | 9.08% |
| 1995 FY | 93.6 Million USD | 100.43% |
| 1995 Q3 | 93.2 Million USD | 0.0% |
| 1995 Q1 | 45.2 Million USD | -3.21% |
| 1995 Q4 | 93.6 Million USD | 0.43% |
| 1994 Q4 | 46.7 Million USD | -10.36% |
| 1994 Q2 | 36 Million USD | -16.67% |
| 1994 Q3 | 52.1 Million USD | 44.72% |
| 1994 FY | 46.7 Million USD | 0.0% |
| 1994 Q1 | 43.2 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 44.018% |
| Alkermes plc | 2.13 Billion USD | 61.003% |
| Agenus Inc. | 313.91 Million USD | -165.381% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 78.248% |
| Aptorum Group Limited | 20.64 Million USD | -3936.145% |
| Ardelyx, Inc. | 297.57 Million USD | -179.947% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -8.819% |
| Bicycle Therapeutics plc | 595.34 Million USD | -39.93% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -1030.314% |
| ChromaDex Corporation | 54.96 Million USD | -1415.654% |
| Chimerix, Inc. | 212.77 Million USD | -291.525% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2846.563% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -88.917% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 62.636% |
| Precision BioSciences, Inc. | 159.78 Million USD | -421.379% |
| Dyadic International, Inc. | 8.21 Million USD | -10035.541% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2524.65% |
| Fortress Biotech, Inc. | 167.52 Million USD | -397.274% |
| Lantern Pharma Inc. | 43.64 Million USD | -1808.613% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -416.35% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -5642.636% |
| Incyte Corporation | 6.78 Billion USD | 87.717% |
| IO Biotech, Inc. | 150.71 Million USD | -452.73% |
| Jaguar Health, Inc. | 50.76 Million USD | -1541.085% |
| Novavax, Inc. | 1.85 Billion USD | 55.099% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -118.993% |
| Opthea Limited | 188.79 Million USD | -341.262% |
| ContextLogic Inc. | 423 Million USD | -96.942% |
| MiMedx Group, Inc. | 239.04 Million USD | -248.494% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -379.528% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -16014.356% |
| NextCure, Inc. | 129.41 Million USD | -543.7% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1444.198% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -2168.137% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2479.066% |
| Vaxcyte, Inc. | 1.4 Billion USD | 40.83% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1302.699% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -30.055% |
| Pharming Group N.V. | 462.85 Million USD | -79.984% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -2053.733% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -32.536% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4302.232% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4302.232% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -403.91% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1739.521% |
| Acelyrin, Inc. | 742.69 Million USD | -12.168% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -12548.009% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -12910.526% |
| Summit Therapeutics Inc. | 202.94 Million USD | -310.479% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -1020.101% |
| Senti Biosciences, Inc. | 119.48 Million USD | -597.218% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -264.832% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -395.358% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -9981.859% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -17350.869% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -77.553% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -573.711% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -202.989% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -76.183% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -8144.077% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -288.364% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -73481.891% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -101.3% |
| Immix Biopharma, Inc. | 19.92 Million USD | -4080.965% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -125.137% |
| MEI Pharma, Inc. | 41.37 Million USD | -1913.448% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2470.709% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -144.445% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -610.654% |
| Fortress Biotech, Inc. | 167.52 Million USD | -397.274% |
| Precigen, Inc. | 151.04 Million USD | -451.541% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2348.892% |
| AlloVir, Inc. | 190.79 Million USD | -336.626% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -121.294% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -64.567% |
| ImmuCell Corporation | 43.8 Million USD | -1801.621% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -28.299% |
| Onconetix, Inc. | 88.82 Million USD | -837.909% |
| PureTech Health plc | 693.97 Million USD | -20.043% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -752.806% |
| Elevation Oncology, Inc. | 89.09 Million USD | -835.071% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -13332.183% |
| Seer, Inc. | 436.26 Million USD | -90.952% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -920.949% |
| Innoviva, Inc. | 1.24 Billion USD | 33.007% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -529.093% |
| ESSA Pharma Inc. | 149.12 Million USD | -458.645% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1738.325% |
| GT Biopharma, Inc. | 14.1 Million USD | -5804.486% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -170.569% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -244.664% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -76.531% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1543.221% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -774.957% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -131799.909% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -47.096% |
| Aptose Biosciences Inc. | 12.92 Million USD | -6346.594% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3667.086% |
| Soligenix, Inc. | 9.79 Million USD | -8402.973% |
| Century Therapeutics, Inc. | 360.69 Million USD | -130.963% |
| Kura Oncology, Inc. | 448.93 Million USD | -85.565% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -206.106% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -4716.791% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -651.108% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -306.074% |
| Autolus Therapeutics plc | 375.38 Million USD | -121.925% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -231.059% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -134.544% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1595.563% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -26.005% |
| GRI Bio, Inc. | 2.95 Million USD | -28082.138% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -7755.222% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -388.558% |
| IGM Biosciences, Inc. | 423.41 Million USD | -96.751% |
| INmune Bio, Inc. | 57 Million USD | -1361.49% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -274.401% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -892.437% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3089.756% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -12002.868% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -1007.415% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -465.717% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -403.35% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -32.316% |
| Verastem, Inc. | 149.71 Million USD | -456.422% |
| Abeona Therapeutics Inc. | 64 Million USD | -1201.622% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -62.659% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -439.35% |
| Histogen Inc. | 19.07 Million USD | -4267.766% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -3577.959% |
| Surrozen, Inc. | 46.08 Million USD | -1707.865% |
| Organovo Holdings, Inc. | 6.34 Million USD | -13021.184% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -19234.822% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -478.409% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -6958.668% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -1006.797% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -9678.607% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -129.514% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -4503.989% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -94.006% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -6505.475% |
| Apollomics, Inc. | 55.38 Million USD | -1404.079% |
| Amarin Corporation plc | 831.68 Million USD | -0.166% |
| Mesoblast Limited | 669.15 Million USD | -24.495% |
| Turnstone Biologics Corp. | 112.81 Million USD | -638.434% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -44.69% |
| Synaptogenix, Inc. | 31.11 Million USD | -2577.486% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -6737.36% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -52.002% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -14086.427% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -11241.674% |
| Exelixis, Inc. | 2.94 Billion USD | 71.687% |
| Better Therapeutics, Inc. | 22.94 Million USD | -3531.016% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -128.525% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -5.621% |
| NLS Pharmaceutics AG | 1.84 Million USD | -45012.396% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -10341.186% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -5569.03% |
| Gritstone bio, Inc. | 177.76 Million USD | -368.622% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -773.416% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -4563.819% |
| Avid Bioservices, Inc. | 336.55 Million USD | -147.525% |
| Insmed Incorporated | 1.32 Billion USD | 37.356% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -8552.203% |
| MediWound Ltd. | 66.45 Million USD | -1153.501% |
| OmniAb, Inc. | 401.98 Million USD | -107.238% |
| Alector, Inc. | 621.82 Million USD | -33.97% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -132.31% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -15390.219% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1369.456% |
| Zai Lab Limited | 1.03 Billion USD | 19.611% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -74.116% |
| Aura Biosciences, Inc. | 255.07 Million USD | -226.596% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -11.071% |
| Immunic, Inc. | 54.29 Million USD | -1434.216% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -212.918% |
| Veracyte, Inc. | 1.13 Billion USD | 26.784% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -6946.26% |
| FibroGen, Inc. | 423.52 Million USD | -96.696% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -23613.749% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -17487.787% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -15243.353% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 92.688% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -9361.261% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -60.993% |
| TG Therapeutics, Inc. | 329.58 Million USD | -152.76% |
| Galecto, Inc. | 38.22 Million USD | -2079.256% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2805.091% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 80.881% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -253.887% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -3253.45% |
| XBiotech Inc. | 227.24 Million USD | -266.596% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -773.416% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -484.196% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -191.367% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -551.498% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -118.08% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 44.128% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -128.336% |
| Vaxxinity, Inc. | 44.35 Million USD | -1778.259% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -61.147% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -4376.593% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -173.091% |
| NexImmune, Inc. | 8.59 Million USD | -9593.611% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -7674.608% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -4763.928% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.482% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3660.819% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -212272.758% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -380.626% |
| Ainos, Inc. | 31.84 Million USD | -2516.259% |
| Pluri Inc. | 39.52 Million USD | -2007.582% |
| Prothena Corporation plc | 696.38 Million USD | -19.627% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -194.769% |
| Celularity Inc. | 143.88 Million USD | -478.963% |
| Rallybio Corporation | 115.62 Million USD | -620.519% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1253.915% |
| MeiraGTx Holdings plc | 458.16 Million USD | -81.825% |
| Omeros Corporation | 378.26 Million USD | -120.231% |
| Humacyte, Inc. | 128.22 Million USD | -549.699% |
| Immunocore Holdings plc | 597 Million USD | -39.541% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2565.037% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1115.619% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 20.604% |
| CalciMedica, Inc. | 12.18 Million USD | -6736.799% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -228.431% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -387.434% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -167.836% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -47.367% |
| Pulmatrix, Inc. | 33.95 Million USD | -2353.219% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2968.828% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -491.421% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 35.966% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -539.888% |
| Cytokinetics, Incorporated | 824.31 Million USD | -1.061% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3843.872% |
| Nutriband Inc. | 7.51 Million USD | -10982.173% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -955.126% |
| Vor Biopharma Inc. | 209.82 Million USD | -297.022% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 88.466% |
| Evogene Ltd. | 51.1 Million USD | -1530.23% |
| ProKidney Corp. | 420.55 Million USD | -98.088% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1419.275% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -8650.417% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -52.47% |
| CorMedix Inc. | 82.05 Million USD | -915.189% |
| BioLineRx Ltd. | 63.92 Million USD | -1203.19% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -106.938% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2854.128% |
| Atai Life Sciences N.V. | 293.47 Million USD | -183.859% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -410.677% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -553.804% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -48.225% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -761.324% |
| MediciNova, Inc. | 66.26 Million USD | -1157.076% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -847.223% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -18568.666% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8873.87% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -41.621% |
| Biomea Fusion, Inc. | 199.92 Million USD | -316.684% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 56.228% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1152.747% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -71.732% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -35.926% |
| Absci Corporation | 234.48 Million USD | -255.281% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -11288.435% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -145.097% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -404.636% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -58.28% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -199.995% |
| Allakos Inc. | 243.61 Million USD | -241.966% |
| Imunon, Inc. | 21.91 Million USD | -3700.809% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -223.276% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -34.037% |
| BioAtla, Inc. | 119.65 Million USD | -596.204% |
| NLS Pharmaceutics AG | 1.84 Million USD | -45012.396% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -25771.553% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -29.592% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -768.363% |
| XOMA Corporation | 234.3 Million USD | -255.553% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -276.552% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -561.982% |
| aTyr Pharma, Inc. | 122.06 Million USD | -582.465% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -441.292% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -43.565% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -69.866% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -654.116% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -5396.03% |
| Akari Therapeutics, Plc | 4.35 Million USD | -19028.909% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4789.639% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 51.937% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -26912.574% |
| UroGen Pharma Ltd. | 178.31 Million USD | -367.197% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -76.971% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -149808.496% |
| Orgenesis Inc. | 14.55 Million USD | -5624.739% |
| Entera Bio Ltd. | 11.76 Million USD | -6980.867% |
| GH Research PLC | 226.3 Million USD | -268.124% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1423.136% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -675.405% |
| Xencor, Inc. | 952.69 Million USD | 12.557% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -10602.576% |
| Replimune Group, Inc. | 487.72 Million USD | -70.807% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -10221.581% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -28.472% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -26912.574% |
| Portage Biotech Inc. | 7.77 Million USD | -10609.14% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -18568.666% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -200.805% |
| OncoCyte Corporation | 74.89 Million USD | -1012.354% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -40872.08% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -14296.326% |
| Purple Biotech Ltd. | 44.3 Million USD | -1780.421% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2341.142% |
| scPharmaceuticals Inc. | 94.47 Million USD | -781.745% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -4516.603% |
| HilleVax, Inc. | 344.43 Million USD | -141.865% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -26129.975% |
| Tharimmune, Inc. | 10.94 Million USD | -7510.397% |
| Genprex, Inc. | 10.67 Million USD | -7707.102% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -67.89% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -765.503% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -34238.994% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -19899.419% |
| OKYO Pharma Limited | 1.54 Million USD | -53950.701% |
| Savara Inc. | 177.56 Million USD | -369.163% |
| Curis, Inc. | 77.28 Million USD | -977.953% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3814.367% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1202.705% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -10202.548% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -4200.573% |
| BeiGene, Ltd. | 5.8 Billion USD | 85.65% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -6745.788% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 60.114% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -132.731% |
| Erasca, Inc. | 395.29 Million USD | -110.744% |
| bluebird bio, Inc. | 619.16 Million USD | -34.547% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -19168.862% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 87.824% |
| DBV Technologies S.A. | 182.98 Million USD | -355.261% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -19168.862% |
| Moderna, Inc. | 18.42 Billion USD | 95.479% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -4473.003% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -7090.264% |
| Molecular Templates, Inc. | 35.38 Million USD | -2254.419% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -502.513% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -5.596% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -174.255% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -701.439% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -78.912% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -165.784% |
| MacroGenics, Inc. | 306.82 Million USD | -171.516% |
| RenovoRx, Inc. | 1.46 Million USD | -56725.648% |
| Adicet Bio, Inc. | 207.29 Million USD | -301.874% |
| Prime Medicine, Inc. | 193.85 Million USD | -329.744% |
| Aditxt, Inc. | 44.57 Million USD | -1768.765% |
| Adagene Inc. | 115.72 Million USD | -619.841% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -18602.933% |
| Quantum-Si incorporated | 298.25 Million USD | -179.317% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 43.994% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -10706.21% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -137.15% |
| SciSparc Ltd. | 11.18 Million USD | -7350.045% |
| Vericel Corporation | 353.65 Million USD | -135.557% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6721.343% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1364.069% |
| Generation Bio Co. | 374.75 Million USD | -122.294% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -227.12% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -425.37% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -144.039% |
| Invivyd, Inc. | 229.18 Million USD | -263.496% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 1.293% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -6745.619% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -356.749% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3978.848% |
| 2seventy bio, Inc. | 565.42 Million USD | -47.334% |
| ADMA Biologics, Inc. | 329.18 Million USD | -153.071% |
| Clene Inc. | 52.34 Million USD | -1491.609% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1318.36% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -541.341% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8873.87% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -27.438% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -704.029% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -538.921% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -753.969% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -1073.379% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -243.456% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 57.499% |
| Evaxion Biotech A/S | 12.88 Million USD | -6363.563% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -230.502% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -10.679% |
| Trevena, Inc. | 40.6 Million USD | -1951.629% |
| Surrozen, Inc. | 46.08 Million USD | -1707.865% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -268.846% |
| Cingulate Inc. | 3.49 Million USD | -23760.211% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4909.706% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1168.175% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -7029.573% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -210.246% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -11.23% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -561.729% |
| Clearmind Medicine Inc. | 4.32 Million USD | -19164.317% |
| Kronos Bio, Inc. | 213.27 Million USD | -290.598% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -421.369% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9631.363% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -126.075% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3835.174% |
| ImmunityBio, Inc. | 504.45 Million USD | -65.142% |
| Korro Bio, Inc. | 221.66 Million USD | -275.825% |
| Kineta, Inc. | 10.28 Million USD | -8002.947% |
| BioVie Inc. | 25.2 Million USD | -3204.715% |
| Codexis, Inc. | 136.56 Million USD | -510.031% |
| Celularity Inc. | 143.88 Million USD | -478.963% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -31.118% |
| Celcuity Inc. | 191.21 Million USD | -335.659% |
| Virax Biolabs Group Limited | 5.48 Million USD | -15090.895% |
| Cibus, Inc. | 544.41 Million USD | -53.021% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -561.719% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3955.023% |
| IN8bio, Inc. | 33.7 Million USD | -2371.34% |
| Kodiak Sciences Inc. | 479.37 Million USD | -73.782% |
| Annexon, Inc. | 297.67 Million USD | -179.858% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -381.512% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -506.001% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3868.294% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 72.139% |
| Eyenovia, Inc. | 28.77 Million USD | -2794.656% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -261.372% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -11431.894% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1267.337% |
| Arcellx, Inc. | 825.13 Million USD | -0.961% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -920.449% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -80.21% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2609.151% |
| Moolec Science SA | 24.05 Million USD | -3363.698% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -168.622% |
| Geron Corporation | 394.07 Million USD | -111.397% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -719.058% |
| Royalty Pharma plc | 16.38 Billion USD | 94.915% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -40.018% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -11809.736% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -6826.433% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -268.515% |
| Humacyte, Inc. | 128.22 Million USD | -549.699% |
| Structure Therapeutics Inc. | 482.01 Million USD | -72.829% |
| 89bio, Inc. | 596.26 Million USD | -39.713% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -230.382% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -44930.486% |
| Genelux Corporation | 27.89 Million USD | -2886.642% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -831.808% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -263.103% |
| Notable Labs, Ltd. | 19.54 Million USD | -4163.16% |
| Liquidia Corporation | 120.43 Million USD | -591.736% |
| Mustang Bio, Inc. | 17.74 Million USD | -4595.435% |
| Immunovant, Inc. | 666.71 Million USD | -24.951% |
| Quantum-Si incorporated | 298.25 Million USD | -179.317% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -476.91% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1438.154% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -374.556% |
| Acasti Pharma Inc. | 73.3 Million USD | -1036.513% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -18199.925% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3089.756% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 13.654% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -15951.583% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -3556.837% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1514.371% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -361.043% |
| PepGen Inc. | 143.05 Million USD | -482.35% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -2079.826% |
| United Therapeutics Corporation | 7.16 Billion USD | 88.376% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -4242.267% |
| Solid Biosciences Inc. | 164.93 Million USD | -405.074% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -14086.427% |
| Immuneering Corporation | 102.58 Million USD | -712.076% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -19234.822% |
| Silo Pharma, Inc. | 7.74 Million USD | -10654.568% |
| Belite Bio, Inc | 94.64 Million USD | -780.227% |
| XOMA Corporation | 234.3 Million USD | -255.553% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -257.25% |
| Bionomics Limited | 27.64 Million USD | -2912.989% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -107.538% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -675.751% |
| uniQure N.V. | 831.68 Million USD | -0.165% |
| Cassava Sciences, Inc. | 151.66 Million USD | -449.286% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -18602.933% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -204.166% |
| Forte Biosciences, Inc. | 38.98 Million USD | -2037.158% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -20352.754% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -2161.856% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -11431.894% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -23613.749% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -6947.323% |
| Altimmune, Inc. | 210.64 Million USD | -295.492% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -7.094% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -675.751% |
| Compugen Ltd. | 121.33 Million USD | -586.587% |
| Peak Bio, Inc. | 2.59 Million USD | -31985.164% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -383.42% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1495.602% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -143.686% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2295.721% |
| Zura Bio Limited | 100.84 Million USD | -726.1% |
| PolyPid Ltd. | 15.37 Million USD | -5319.36% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -598.375% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2295.721% |
| Instil Bio, Inc. | 325.63 Million USD | -155.831% |
| argenx SE | 4.54 Billion USD | 81.661% |
| Immunome, Inc. | 148.54 Million USD | -460.835% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -431.037% |
| Verona Pharma plc | 308.12 Million USD | -170.366% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -857.996% |
| Shattuck Labs, Inc. | 159.56 Million USD | -422.088% |
| CervoMed Inc. | 9.97 Million USD | -8253.595% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -342.047% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -7215.279% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -364.348% |
| Moolec Science SA | 24.05 Million USD | -3363.698% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -13517.764% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -381.695% |
| AnaptysBio, Inc. | 452.38 Million USD | -84.148% |
| Design Therapeutics, Inc. | 289.64 Million USD | -187.618% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -1043.926% |
| NeurAxis, Inc. | 509.49 Thousand USD | -163406.824% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -15275.858% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1949.963% |
| Achilles Therapeutics plc | 161.45 Million USD | -415.97% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -857.996% |
| 180 Life Sciences Corp. | 5.25 Million USD | -15739.297% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1082.862% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9631.363% |
| Nutriband Inc. | 7.51 Million USD | -10982.173% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -227.095% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -317.993% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -993.088% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1338.4% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -58.215% |
| Palisade Bio, Inc. | 14.05 Million USD | -5828.437% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -296.141% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 42.93% |
| Neurogene Inc. | 222.57 Million USD | -274.288% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -28.833% |
| AEON Biopharma, Inc. | 6.84 Million USD | -12070.402% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -83.885% |
| Sesen Bio, Inc. | 189.17 Million USD | -340.369% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -206.423% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -5975.495% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -6.755% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -212.016% |
| Athira Pharma, Inc. | 160.24 Million USD | -419.869% |
| Vaccinex, Inc. | 3.63 Million USD | -22843.101% |
| HCW Biologics Inc. | 28.51 Million USD | -2821.631% |
| XOMA Corporation | 234.3 Million USD | -255.553% |
| Nektar Therapeutics | 398.03 Million USD | -109.295% |
| Arvinas, Inc. | 1.3 Billion USD | 36.144% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4789.639% |
| Merus N.V. | 458.49 Million USD | -81.696% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -307.633% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -362.289% |
| Rezolute, Inc. | 132.73 Million USD | -527.605% |
| Clene Inc. | 52.34 Million USD | -1491.609% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -5482.088% |
| BeyondSpring Inc. | 24.8 Million USD | -3258.046% |
| Synlogic, Inc. | 75.55 Million USD | -1002.666% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -6922.964% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -8796.455% |
| Peak Bio, Inc. | 2.59 Million USD | -31985.164% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -376.491% |
| Krystal Biotech, Inc. | 818.35 Million USD | -1.797% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -246.478% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -14.781% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -23188.328% |
| MannKind Corporation | 475.19 Million USD | -75.309% |
| Ikena Oncology, Inc. | 192.09 Million USD | -333.68% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -6128.982% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -614.837% |
| Gossamer Bio, Inc. | 311.91 Million USD | -167.08% |
| CohBar, Inc. | 16.36 Million USD | -4990.315% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2269.149% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -11288.435% |
| Legend Biotech Corporation | 1.84 Billion USD | 54.936% |
| Mural Oncology plc | 301.74 Million USD | -176.082% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2568.794% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -14565.574% |
| Disc Medicine, Inc. | 367.99 Million USD | -126.379% |
| Champions Oncology, Inc. | 26.13 Million USD | -3087.908% |
| REGENXBIO Inc. | 573.97 Million USD | -45.141% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -30662.107% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -439.598% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -6798.749% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -144.994% |
| Vaxart, Inc. | 91.83 Million USD | -807.181% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1290.668% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -461.64% |
| Cellectis S.A. | 334.27 Million USD | -149.219% |
| Longeveron Inc. | 12.17 Million USD | -6740.729% |
| Repare Therapeutics Inc. | 253.9 Million USD | -228.106% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 74.482% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -314.775% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 60.114% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -51165.477% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -199.975% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -410.775% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -500.432% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -3164.102% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.335% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 27.806% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6721.343% |
| Veru Inc. | 50.59 Million USD | -1546.504% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1728.78% |
| Cingulate Inc. | 3.49 Million USD | -23760.211% |
| Passage Bio, Inc. | 150.54 Million USD | -453.365% |
| Context Therapeutics Inc. | 16.06 Million USD | -5086.315% |
| Exicure, Inc. | 11.58 Million USD | -7093.99% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -121.531% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -415.376% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -4667.995% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -150.361% |
| Nuvalent, Inc. | 732.38 Million USD | -13.747% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -5474.542% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -830.237% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -5770.369% |
| OmniAb, Inc. | 401.98 Million USD | -107.238% |
| Anew Medical, Inc. | 19.45 Million USD | -4181.795% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -3016.99% |
| Lipocine Inc. | 23 Million USD | -3521.849% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -495.867% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -172.631% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -892.437% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -585.424% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -10398.601% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 5.578% |
| Ocugen, Inc. | 64.54 Million USD | -1190.632% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -568.907% |
| Q32 Bio Inc. | 306.11 Million USD | -172.137% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -19697.148% |
| Alumis Inc. Common Stock | 89.61 Million USD | -829.634% |
| Equillium, Inc. | 50.53 Million USD | -1548.652% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -1007.872% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1918.398% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -48879.189% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -3086.81% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1192.755% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -22251.455% |
| Dominari Holdings Inc. | 57.55 Million USD | -1347.347% |
| Edesa Biotech, Inc. | 8.89 Million USD | -9270.338% |
| vTv Therapeutics Inc. | 11.01 Million USD | -7460.937% |
| Bio-Techne Corporation | 2.81 Billion USD | 70.387% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 11.104% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -2.664% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -200.025% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1897.66% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -24.787% |
| Nkarta, Inc. | 378.88 Million USD | -119.873% |
| BioCardia, Inc. | 2.98 Million USD | -27789.655% |
| Iterum Therapeutics plc | 26.25 Million USD | -3072.489% |